Authors
Kaitlyn R Scheunemann, Katrina E V Jones, Kimberly Young, Chongben Zhang, Cody McGrath, Kimberly R Love, Michala de Linde Henriksen
Published in
Veterinary ophthalmology. Volume 29. Issue 6. Pages e70280.
Abstract
To evaluate the effect of flunixin meglumine, a systemic non-steroidal anti-inflammatory drug (NSAID), on the antiproteases, A2M and A1AT, in equine plasma and PRF.
A prospective cross-sectional study. Plasma, solid PRF, and liquid PRF were collected from a control-group that included healthy horses not treated with NSAIDs within the last 3 months. The NSAID-group were ophthalmology patients with no systemic inflammatory disease, and all received a full dose of flunixin meglumine (1.1 mg/kg BID PO or IV) for three or more days prior to collection. Samples were collected and prepared using a standardized protocol for plasma and PRF preparation. Concentrations of A2M and A1AT were analyzed with ELISA kits. Statistical analysis with Mann-Whitney U tests and Wilcoxon signed-rank tests was performed using significance set at p < 0.05.
No significant differences were found between the control-group (n = 12) and NSAID-group (n = 12) for any of the blood products (p > 0.05). Plasma had a significantly higher amount of A2M compared to solid and liquid PRF (both p < 0.001). Solid PRF had the highest concentration of A1AT and was significantly higher when compared to liquid PRF (p < 0.001), but not when compared to plasma (p = 0.071).
The systemic NSAID, flunixin meglumine, does not appear to significantly alter antiprotease concentrations in equine plasma or PRF. Although PRF should not be used as a replacement for plasma, solid PRF may be a good adjunctive therapy for the treatment of keratomalacia due to its high A1AT concentration.
PMID:
42888515
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 26
- Comments 0